Baroness Professor Susan Greenfield Chief Scientific Officer and Founder
Baroness Susan Greenfield CBE, co-founder of Neuro-Bio, conducts research on novel mechanisms of neurodegeneration at the University of Oxford. She has received 30 Honorary Degrees from British and foreign universities. Other awards include Michael Faraday Medal from the Royal Society (1998), Honorary Fellowship of the Royal College of Physicians (2000), L'Ordre National de la Légion d'Honneur (2003), American Academy of Achievement Golden Plate Award (2003), Honorary Fellowship of the Royal Society of Edinburgh (2007) and Australian Medical Research Society Medal (2010). To find out more go to www.susangreenfield.com.
To contact Susan email: Susan.Greenfield@neuro-bio.com
Charles Morgan Chairman and Non-Executive Director
Dr Morgan has successfully identified emerging international opportunities and is strategically positioned in a wide range of ventures around the globe. His particular strengths include partnering with regional and technology experts, securing teams of appropriate executives and to develop businesses. Mr Morgan has extensive experience in equity capital markets and has been involved with numerous projects over a 20 year period.
Dr Linda E Cammish, MBA Board Adviser
Dr Cammish has over 25 years experience in the life science sector in businesses offering products and services including reagents, hardware, software and drug discovery services and technology access programmes, selling into the academic, pharmaceutical and biotechnology markets. Her background includes extensive experience in senior general management, business development, sales and marketing roles in companies including Millipore, PerSeptive Biosystems, Applied Biosystems and Abcam. More recently she was CEO at nanoTherics where she raised significant investment for the company, established a company infrastructure and grew revenues with double digit sales growth year on year. She currently is a Non-Executive Director for several life science based organisations. She holds a Ph.D. from the University of Cambridge and an MBA from Henley Management College.
To contact Linda email: firstname.lastname@example.org
Dr Gwënaël Pottiez Senior Biochemist
Dr Gwënaël Pottiez holds a Ph.D in Biochemistry, Master of Science and Bachelor of Science and is the biochemical expert in the team. His recent experience is working with Professor Greenfield at Oxford University. Dr Pottiez research includes the structure of the anatomical barrier separating the brain tissue from the blood stream which is a significant knowledge asset in neuroscience drug development. His post-doctoral project of research was based on the discovery of biomarkers in relation to viral infection, analyzing patient's blood. This provided him knowledge on clinical research and biomarker discovery related to human pathologies. His skills set include chemistry of proteins, pharmacology, mass spectrometry and software. Dr Pottiez has eight years project management of research projects and he enjoys the challenge to push scientific boundaries. Dr Pottiez is the main inventor, with Professor Susan Greenfield, in a Patent recently filed for biomarkers for Alzheimer's disease. Dr Pottiez has already been published fifteen times and has two book chapters to his name.
To contact Gwen email: Gwenael.Pottiez@neuro-bio.com
Dr Sara Garcia Ratés Senior Neurobiologist
Sara Garcia Ratés holds a PhD in Research, Development and Drug Control from the University of Barcelona (Spain) with the thesis "Interaction of the amphetamine derivates with the nicotinic receptors: Molecular and functional aspects". Her interest in the non-traditional properties of the nicotinic receptor attracted her to the position at the Department of Pharmacology of Oxford University as a Postdoctoral Researcher with Baroness Susan Greenfield, who explores novel approaches to neurodegeneration. This group published extensively on non-traditional actions of acetylcholinesterase (AchE) focusing their novel theory on the non-traditional actions of this 'AChE-peptide' and the interaction with an alternative or allosteric site of the α7-nAChR. Her particular project was concerned with the immediate therapeutic strategy to characterize the binding of the peptide to the specific receptor site in order to arrest further cell loss and then intercepting its further action that lead her to find a possible novel and effective candidate to cure Alzheimer's and other neurodegenerative diseases.
To contact Sara email: Sara.GarciaRates@neuro-bio.com
Mr Scott Badin Pharmacologist
Mr. Scott Badin holds a BSc (H) in Biological Sciences (Pharmacology) from The University of Edinburgh, and is now finishing his PhD in neuropharmacology at The University of Oxford. Mr. Badin is the pharmacologist expert of the group and focuses his research on the use of electrophysiology and voltage-sensitive dye imaging (VSDI) in order to monitor cortical activity at the meso-scale of brain organisation at physiologically-relevant spatio-temporal resolution (of millisecond and micrometers). Mr. Badin's first publication investigated the acute bioactivity of acetylcholine esterase-related peptides on in vitro cortical networks and validated the use of such on-line recording techniques as an adequate screening tool for probing the bioactivity and efficacy of drugs.
To contact Scott email: Scott.Badin@neuro-bio.com
Miss Emily Smith Office Manager and PA to Baroness Greenfield
Emily Smith has had a wide range of experience in the service industry, from catering to leisure organisations: however for the last 18 months she has been personal assistant to Baroness Greenfield dealing with a range of sectors including academia, the media, finance and politics (House of Lords).
To contact Emily email: email@example.com